JP4672368B2 - 副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用 - Google Patents
副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用 Download PDFInfo
- Publication number
- JP4672368B2 JP4672368B2 JP2004544592A JP2004544592A JP4672368B2 JP 4672368 B2 JP4672368 B2 JP 4672368B2 JP 2004544592 A JP2004544592 A JP 2004544592A JP 2004544592 A JP2004544592 A JP 2004544592A JP 4672368 B2 JP4672368 B2 JP 4672368B2
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- formula
- hydrogen
- lower alkyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C[C@](CCC[C@@](*)(*1)[C@@]1C[C@](*C(C[C@@](C(C)(C)C([C@@]1C)=O)O)=O)C(C)=Cc2c[s]c(*)n2)[C@]1O Chemical compound C[C@](CCC[C@@](*)(*1)[C@@]1C[C@](*C(C[C@@](C(C)(C)C([C@@]1C)=O)O)=O)C(C)=Cc2c[s]c(*)n2)[C@]1O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41859202P | 2002-10-15 | 2002-10-15 | |
| PCT/IB2003/004514 WO2004035050A1 (en) | 2002-10-15 | 2003-10-13 | Use of epothilone derivatives for the treatment of hyperparathyroidism |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006504751A JP2006504751A (ja) | 2006-02-09 |
| JP2006504751A5 JP2006504751A5 (enExample) | 2006-11-30 |
| JP4672368B2 true JP4672368B2 (ja) | 2011-04-20 |
Family
ID=32107949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004544592A Expired - Fee Related JP4672368B2 (ja) | 2002-10-15 | 2003-10-13 | 副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20060142354A1 (enExample) |
| EP (1) | EP1553938B1 (enExample) |
| JP (1) | JP4672368B2 (enExample) |
| CN (1) | CN1297269C (enExample) |
| AT (1) | ATE350034T1 (enExample) |
| AU (1) | AU2003267751A1 (enExample) |
| BR (1) | BR0315293A (enExample) |
| CA (1) | CA2501717C (enExample) |
| CY (1) | CY1106385T1 (enExample) |
| DE (1) | DE60310975T2 (enExample) |
| DK (1) | DK1553938T3 (enExample) |
| ES (1) | ES2279139T3 (enExample) |
| PT (1) | PT1553938E (enExample) |
| SI (1) | SI1553938T1 (enExample) |
| WO (1) | WO2004035050A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| CA2496477C (en) | 2002-08-23 | 2012-10-16 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1155689E (pt) * | 1993-07-19 | 2007-01-31 | Angiotech Pharm Inc | Composições anti-angiogenicas e metodos de utilização |
| WO1998022461A1 (de) * | 1996-11-18 | 1998-05-28 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel |
| US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| KR20080016756A (ko) * | 1998-02-05 | 2008-02-21 | 노파르티스 아게 | 유기화합물 함유 조성물 |
| US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
-
2003
- 2003-10-13 WO PCT/IB2003/004514 patent/WO2004035050A1/en not_active Ceased
- 2003-10-13 ES ES03748446T patent/ES2279139T3/es not_active Expired - Lifetime
- 2003-10-13 SI SI200330741T patent/SI1553938T1/sl unknown
- 2003-10-13 AT AT03748446T patent/ATE350034T1/de active
- 2003-10-13 US US10/530,855 patent/US20060142354A1/en not_active Abandoned
- 2003-10-13 AU AU2003267751A patent/AU2003267751A1/en not_active Abandoned
- 2003-10-13 JP JP2004544592A patent/JP4672368B2/ja not_active Expired - Fee Related
- 2003-10-13 PT PT03748446T patent/PT1553938E/pt unknown
- 2003-10-13 DE DE60310975T patent/DE60310975T2/de not_active Expired - Lifetime
- 2003-10-13 CA CA2501717A patent/CA2501717C/en not_active Expired - Fee Related
- 2003-10-13 BR BR0315293-6A patent/BR0315293A/pt not_active IP Right Cessation
- 2003-10-13 CN CNB200380101281XA patent/CN1297269C/zh not_active Expired - Fee Related
- 2003-10-13 EP EP03748446A patent/EP1553938B1/en not_active Expired - Lifetime
- 2003-10-13 DK DK03748446T patent/DK1553938T3/da active
-
2007
- 2007-03-15 CY CY20071100363T patent/CY1106385T1/el unknown
-
2011
- 2011-03-01 US US13/037,989 patent/US20110152329A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1080768A1 (en) | 2006-05-04 |
| JP2006504751A (ja) | 2006-02-09 |
| DE60310975D1 (de) | 2007-02-15 |
| DE60310975T2 (de) | 2007-07-12 |
| CN1703217A (zh) | 2005-11-30 |
| ES2279139T3 (es) | 2007-08-16 |
| CY1106385T1 (el) | 2011-10-12 |
| AU2003267751A1 (en) | 2004-05-04 |
| US20110152329A1 (en) | 2011-06-23 |
| EP1553938A1 (en) | 2005-07-20 |
| CA2501717A1 (en) | 2004-04-29 |
| CN1297269C (zh) | 2007-01-31 |
| ATE350034T1 (de) | 2007-01-15 |
| CA2501717C (en) | 2012-09-18 |
| BR0315293A (pt) | 2005-08-30 |
| PT1553938E (pt) | 2007-03-30 |
| DK1553938T3 (da) | 2007-03-26 |
| US20060142354A1 (en) | 2006-06-29 |
| SI1553938T1 (sl) | 2007-06-30 |
| WO2004035050A1 (en) | 2004-04-29 |
| EP1553938B1 (en) | 2007-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1701725B1 (en) | Compositions comprising flupirtine and an opioid for use in the treatment of neuropathic pain | |
| JP6846392B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤 | |
| US20040146498A1 (en) | Pharmaceutical combinations | |
| US20090246172A1 (en) | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome | |
| AU2002305952A1 (en) | Pharmaceutical combinations | |
| JP3832229B2 (ja) | フェニルエテンスルホンアミド誘導体含有医薬 | |
| CN1356908A (zh) | 包含低分子量凝血酶抑制剂及其药物前体的药用制剂 | |
| JP2016179994A (ja) | イネカルシトールの新しい治療的使用 | |
| EP2254570A1 (en) | Combination comprising paclitaxel for treating ovarian cancer | |
| MXPA04010853A (es) | Derivado de epotilona para el tratamiento de hepatoma y otras enfermedades de cancer. | |
| JP4672368B2 (ja) | 副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用 | |
| JP2020520374A (ja) | 関節リウマチの治療用組成物および治療方法 | |
| HK1080768B (en) | Use of epothilone derivatives for the treatment of hyperparathyroidism | |
| AU2002366531B2 (en) | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome | |
| WO2009104152A1 (en) | Combination treatment for ovarian cancer | |
| JP2004250441A (ja) | 血小板大凝集塊の形成阻害剤 | |
| HK1069983B (en) | Compositions comprising epothilones and their use for the treatment of the carcinoid syndrome | |
| ZA200404013B (en) | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061012 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061012 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20091224 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100202 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100506 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100513 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100519 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100803 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101102 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101110 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110111 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110119 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140128 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |